The Deleterious Influence of Tenofovir-Based Therapies on the Progression of Atherosclerosis in HIV-Infected Patients
We investigated the potential differential effects of antiretroviral therapies on unbalanced chemokine homeostasis and on the progression of atherosclerosis in HIV-infected patients. A two-year prospective study was performed in 67 consecutive HIV-infected patients initiating antiretroviral therapy...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2012/372305 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849696188178104320 |
|---|---|
| author | Gerard Aragonès Pedro Pardo-Reche Laura Fernández-Sender Anna Rull Raúl Beltrán-Debón Esther Rodríguez-Gallego Jordi Camps Jorge Joven Carlos Alonso-Villaverde |
| author_facet | Gerard Aragonès Pedro Pardo-Reche Laura Fernández-Sender Anna Rull Raúl Beltrán-Debón Esther Rodríguez-Gallego Jordi Camps Jorge Joven Carlos Alonso-Villaverde |
| author_sort | Gerard Aragonès |
| collection | DOAJ |
| description | We investigated the potential differential effects of antiretroviral therapies on unbalanced chemokine homeostasis and on the progression of atherosclerosis in HIV-infected patients. A two-year prospective study was performed in 67 consecutive HIV-infected patients initiating antiretroviral therapy with abacavir/lamivudine or tenofovir/emtricitabine. Circulating levels of inflammatory biomarkers, progression of subclinical atherosclerosis and expression levels of selected chemokines genes in circulating leukocytes were assessed. Control subjects showed significantly lower plasma concentrations of CRP, tPA, IL-6, and MCP-1 than HIV-infected patients at a baseline. After two years of followup, the observed decreases in plasma inflammatory biomarker levels were only significant for MCP-1, tPA, and IL-6. The decrease in plasma MCP-1 concentration was associated with the progression of atherosclerosis, and this effect was negligible only in patients receiving TDF-based therapy. Multivariate analysis confirmed that treatment with TDF was positively and significantly associated with a higher likelihood of subclinical atherosclerosis progression. However, the expression levels of selected genes in blood cells only showed associations with the viral load and total and HDL-cholesterol levels. Current antiretroviral treatments may partially attenuate the influence of HIV infection on certain inflammatory pathways, though patients receiving TDF therapy must be carefully monitored with respect to the presence and/or progression of atherosclerosis. |
| format | Article |
| id | doaj-art-ccff7ae448534ceab2d2136d27cc401f |
| institution | DOAJ |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-ccff7ae448534ceab2d2136d27cc401f2025-08-20T03:19:32ZengWileyMediators of Inflammation0962-93511466-18612012-01-01201210.1155/2012/372305372305The Deleterious Influence of Tenofovir-Based Therapies on the Progression of Atherosclerosis in HIV-Infected PatientsGerard Aragonès0Pedro Pardo-Reche1Laura Fernández-Sender2Anna Rull3Raúl Beltrán-Debón4Esther Rodríguez-Gallego5Jordi Camps6Jorge Joven7Carlos Alonso-Villaverde8Unitat de Recerca Biomèdica (URB-CRB), Hospital Universitari Sant Joan, Institut Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili, 43201 Reus, SpainServei de Medicina Interna, Hospital Universitari Sant Joan, Institut Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili, 43204 Reus, SpainServei de Medicina Interna, Hospital Universitari Sant Joan, Institut Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili, 43204 Reus, SpainUnitat de Recerca Biomèdica (URB-CRB), Hospital Universitari Sant Joan, Institut Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili, 43201 Reus, SpainUnitat de Recerca Biomèdica (URB-CRB), Hospital Universitari Sant Joan, Institut Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili, 43201 Reus, SpainUnitat de Recerca Biomèdica (URB-CRB), Hospital Universitari Sant Joan, Institut Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili, 43201 Reus, SpainUnitat de Recerca Biomèdica (URB-CRB), Hospital Universitari Sant Joan, Institut Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili, 43201 Reus, SpainUnitat de Recerca Biomèdica (URB-CRB), Hospital Universitari Sant Joan, Institut Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili, 43201 Reus, SpainUnitat de Recerca Biomèdica (URB-CRB), Hospital Universitari Sant Joan, Institut Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili, 43201 Reus, SpainWe investigated the potential differential effects of antiretroviral therapies on unbalanced chemokine homeostasis and on the progression of atherosclerosis in HIV-infected patients. A two-year prospective study was performed in 67 consecutive HIV-infected patients initiating antiretroviral therapy with abacavir/lamivudine or tenofovir/emtricitabine. Circulating levels of inflammatory biomarkers, progression of subclinical atherosclerosis and expression levels of selected chemokines genes in circulating leukocytes were assessed. Control subjects showed significantly lower plasma concentrations of CRP, tPA, IL-6, and MCP-1 than HIV-infected patients at a baseline. After two years of followup, the observed decreases in plasma inflammatory biomarker levels were only significant for MCP-1, tPA, and IL-6. The decrease in plasma MCP-1 concentration was associated with the progression of atherosclerosis, and this effect was negligible only in patients receiving TDF-based therapy. Multivariate analysis confirmed that treatment with TDF was positively and significantly associated with a higher likelihood of subclinical atherosclerosis progression. However, the expression levels of selected genes in blood cells only showed associations with the viral load and total and HDL-cholesterol levels. Current antiretroviral treatments may partially attenuate the influence of HIV infection on certain inflammatory pathways, though patients receiving TDF therapy must be carefully monitored with respect to the presence and/or progression of atherosclerosis.http://dx.doi.org/10.1155/2012/372305 |
| spellingShingle | Gerard Aragonès Pedro Pardo-Reche Laura Fernández-Sender Anna Rull Raúl Beltrán-Debón Esther Rodríguez-Gallego Jordi Camps Jorge Joven Carlos Alonso-Villaverde The Deleterious Influence of Tenofovir-Based Therapies on the Progression of Atherosclerosis in HIV-Infected Patients Mediators of Inflammation |
| title | The Deleterious Influence of Tenofovir-Based Therapies on the Progression of Atherosclerosis in HIV-Infected Patients |
| title_full | The Deleterious Influence of Tenofovir-Based Therapies on the Progression of Atherosclerosis in HIV-Infected Patients |
| title_fullStr | The Deleterious Influence of Tenofovir-Based Therapies on the Progression of Atherosclerosis in HIV-Infected Patients |
| title_full_unstemmed | The Deleterious Influence of Tenofovir-Based Therapies on the Progression of Atherosclerosis in HIV-Infected Patients |
| title_short | The Deleterious Influence of Tenofovir-Based Therapies on the Progression of Atherosclerosis in HIV-Infected Patients |
| title_sort | deleterious influence of tenofovir based therapies on the progression of atherosclerosis in hiv infected patients |
| url | http://dx.doi.org/10.1155/2012/372305 |
| work_keys_str_mv | AT gerardaragones thedeleteriousinfluenceoftenofovirbasedtherapiesontheprogressionofatherosclerosisinhivinfectedpatients AT pedropardoreche thedeleteriousinfluenceoftenofovirbasedtherapiesontheprogressionofatherosclerosisinhivinfectedpatients AT laurafernandezsender thedeleteriousinfluenceoftenofovirbasedtherapiesontheprogressionofatherosclerosisinhivinfectedpatients AT annarull thedeleteriousinfluenceoftenofovirbasedtherapiesontheprogressionofatherosclerosisinhivinfectedpatients AT raulbeltrandebon thedeleteriousinfluenceoftenofovirbasedtherapiesontheprogressionofatherosclerosisinhivinfectedpatients AT estherrodriguezgallego thedeleteriousinfluenceoftenofovirbasedtherapiesontheprogressionofatherosclerosisinhivinfectedpatients AT jordicamps thedeleteriousinfluenceoftenofovirbasedtherapiesontheprogressionofatherosclerosisinhivinfectedpatients AT jorgejoven thedeleteriousinfluenceoftenofovirbasedtherapiesontheprogressionofatherosclerosisinhivinfectedpatients AT carlosalonsovillaverde thedeleteriousinfluenceoftenofovirbasedtherapiesontheprogressionofatherosclerosisinhivinfectedpatients AT gerardaragones deleteriousinfluenceoftenofovirbasedtherapiesontheprogressionofatherosclerosisinhivinfectedpatients AT pedropardoreche deleteriousinfluenceoftenofovirbasedtherapiesontheprogressionofatherosclerosisinhivinfectedpatients AT laurafernandezsender deleteriousinfluenceoftenofovirbasedtherapiesontheprogressionofatherosclerosisinhivinfectedpatients AT annarull deleteriousinfluenceoftenofovirbasedtherapiesontheprogressionofatherosclerosisinhivinfectedpatients AT raulbeltrandebon deleteriousinfluenceoftenofovirbasedtherapiesontheprogressionofatherosclerosisinhivinfectedpatients AT estherrodriguezgallego deleteriousinfluenceoftenofovirbasedtherapiesontheprogressionofatherosclerosisinhivinfectedpatients AT jordicamps deleteriousinfluenceoftenofovirbasedtherapiesontheprogressionofatherosclerosisinhivinfectedpatients AT jorgejoven deleteriousinfluenceoftenofovirbasedtherapiesontheprogressionofatherosclerosisinhivinfectedpatients AT carlosalonsovillaverde deleteriousinfluenceoftenofovirbasedtherapiesontheprogressionofatherosclerosisinhivinfectedpatients |